Sequential Adjuvant Chemo-Radiotherapy With Vs. Without Erythropoeitin For Patients With High-Risk Cervical Cancer-Second Analysis Of A Prospective, Randomized, Open And Controlled AGO- AND Sequential Adjuvant Chemo-Radiotherapy With Vs. Without Erythropo
Reviewer: Roberto Santiago, MD
The Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 19 de mayo del 2002
Presenter: Jens U Blohmer
Presenter's Affiliation: Humboldt University, Berlin, Germany
Type of Session: Poster
- The aim of the study was to compare the disease-free survival achieved by an adjuvant sequential chemoradiotherapy regimen with vs. without Erythropoeitin (EPO) for patients with high-risk cervical cancer
- The second endpoints of the study included toxicity, number of transfusions, quality of life, and survival
Materials and Methods
- All patients underwent a radical hysterectomy and adjuvant chemotherapy and radiation therapy was recommended postoperatively
- Patients were stratified according to pelvic nodes (pN0 vs. pN1), stage (Ib, IIa vs. IIb), and resection (R0 vs. R1)
- Patients were randomized to sequential chemotherapy followed by radiotherapy with EPO or without EPO
- All patients received 4 cycles (q21d) of ifosphamide (1.6 mg/m2, d1-3), carboplatin (AUC 4, d1) and subsequent radiotherapy (5 weekly fractions of 1.8-2 Gy up to 50-50.5 Gy)
- EPO arm: EPO 10,000 IU three times a week + oral iron supplements up to a Hb target value of 13 g/dl
- No EPO arm: only transfusions were allowed
- 128 patients from 63 clinics were randomized to each arm between 01/1999 and 03/2001
- EPO was given as planned in about half of the patients analyzed in the EPO-arm
- The EPO-application was stopped in 33% of patients because a Hb > 14g/dl was achieved
- The EPO dose was reduced (10.000 IE/3x/week) in 8% of patients because a Hb > 13 g/dl was achieved
- The median doses of carboplatin and ifosphamide (in both arms) were AUC 4 and 1.6 g/m2, respectively
- 84% of the patients completed the 4 cycles of chemotherapy
- Median radiation dose was 50.4 Gy
- Median follow-up was 64.5 weeks
- There was a significantly higher recurrence-free survival rate in the EPO-arm (89% vs. 78%, p=0.04)
- There was a significant reduction of grade 2 anemia (20% vs. 51%, p=0.01) and in the number of red blood cell (no transfusion required: 91% vs. 67%; p=0.0046) as well as platelet transfusions (p=0.0025) in the EPO-arm
- Adjuvant sequential chemoradiotherapy with EPO support in patients with high-risk cervical cancer was demonstrated to be easily tolerated and associated to few treatment interruptions
- After a short follow-up period, support with EPO appeared to afford a lower rate of recurrences
- It is plausible that the benefit seen is due to re-oxygenation of hypoxic tumors but further research is needed to confirm this hypotesis.
- If these findings are confirmed with further follow-up routine EPO support could become a standard component of chemoradiotherapy for cervical cancer.
Oncolink's ASCO Coverage made possible by an unrestricted Educational Grant from Bristol-Myers Squibb Oncology.
I Wish You Knew
How cancer patients have changed my life
Blogs and Web Chats
OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.
Frente a un nuevo diagnóstico de cáncer o de cambiar el curso de su tratamiento actual? Deje que nuestro personal de enfermería cáncer que ayudan a pasar!